Iridex warned on Nasdaq $1 bid price rule
IRIDEX faces a Nasdaq minimum bid price deficiency with 180 days, and possibly another 180, to regain compliance before potential delisting risk.
Rhea-AI Filing Summary
IRIDEX Corporation (IRIX) reports that Nasdaq has notified it of non-compliance with the $1.00 per share minimum bid price requirement for continued listing on the Nasdaq Capital Market, after the stock traded below that level for the last 30 consecutive business days.
Under Nasdaq Listing Rule 5810(c)(3)(A), IRIDEX has a 180-day Cure Period to February 23, 2027 to regain compliance by having its closing bid price at or above $1.00 for at least ten consecutive business days. If it meets other Nasdaq initial listing standards (apart from bid price) and commits to cure the deficiency, including potentially via a reverse stock split, it may receive an additional 180 days. If compliance is not regained, the common stock may be delisted, subject to an appeal process. The company states that the notice has no immediate impact on trading, business operations, or SEC reporting and that it is monitoring its stock price and evaluating options.
Positive
- None.
Negative
- IRIDEX has received a Nasdaq notice that its stock failed to meet the $1.00 minimum bid price for 30 consecutive business days, creating a potential delisting risk if compliance is not restored within the allowed cure periods.
Filing Explained
The deficiency remains in its cure period, with IRIDEX’s common stock continuing to trade on Nasdaq; if used, a reverse stock split would reduce the share count and raise the per-share price proportionally, without changing company value by the split itself.
8-K Event Classification
2 items: 3.01, 9.01
2 items
Item 3.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Securities
The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Minimum Bid Price Requirement: $1.00 per share
Days below minimum bid price: 30 consecutive business days
Initial Cure Period length: 180 calendar days
+3 more
6 metrics
Minimum Bid Price Requirement
$1.00 per share
Nasdaq Listing Rule 5550(a)(2) requirement for continued listing on Nasdaq Capital Market
Days below minimum bid price
30 consecutive business days
Period during which IRIDEX common stock traded below $1.00, triggering the deficiency notice
Initial Cure Period length
180 calendar days
Time from receipt of Nasdaq notice to regain minimum bid price compliance, ending February 23, 2027
Cure Period end date
February 23, 2027
Deadline for IRIDEX to regain compliance in the initial 180-day period
Required compliance streak
10 consecutive business days
Minimum span during which closing bid must be at or above $1.00 to regain compliance
Potential additional cure period
180 calendar days
Extra time Nasdaq may grant if IRIDEX meets other initial listing standards and commits to cure
Key Terms
Minimum Bid Price Requirement, Nasdaq Listing Rule 5550(a)(2), Cure Period, market value of publicly held shares, +1 more
5 terms
Minimum Bid Price Requirement market
"minimum bid price of the Company’s common stock had been below the $1.00 per share minimum requirement"
A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.
Nasdaq Listing Rule 5550(a)(2) regulatory
"minimum requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2)"
Cure Period regulatory
"180 calendar days from receipt of the Notice, or until February 23, 2027, to regain compliance"
A cure period is a set amount of time given to a borrower, counterparty, or contracting party to fix a missed payment, breach, or other problem before more serious consequences—like penalties, higher interest, or contract termination—kick in. For investors, it matters because it creates a short grace window that can prevent immediate losses and influence the timing and likelihood of recovery; think of it like a few extra days to pay a bill before a service is cut off.
reverse stock split financial
"intention to cure the deficiency during the second compliance period, by effecting a reverse stock split"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
FAQ
What Nasdaq compliance issue did IRIDEX (IRIX) disclose?
IRIDEX disclosed it received a Nasdaq notice that its common stock failed to meet the $1.00 per share minimum bid price for 30 consecutive business days, triggering a deficiency under Nasdaq Listing Rule 5550(a)(2) for the Nasdaq Capital Market.
How long does IRIDEX (IRIX) have to regain Nasdaq minimum bid price compliance?
IRIDEX has an initial 180-day Cure Period to February 23, 2027 to regain compliance. It must achieve a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days during this period.
Can IRIDEX (IRIX) obtain more time beyond February 23, 2027 to cure the deficiency?
Yes. If IRIDEX meets all other initial listing standards, including the market value of publicly held shares, and provides written notice of its intent to cure, potentially via a reverse stock split, Nasdaq may grant an additional 180 days to regain minimum bid price compliance.
What happens if IRIDEX (IRIX) does not regain Nasdaq compliance after the cure periods?
If IRIDEX does not qualify for or fails to regain compliance after the allowed cure period(s), Nasdaq staff will notify the company that its common stock will be subject to delisting. IRIDEX would then be entitled to appeal the determination to a Nasdaq hearings panel.
Does the Nasdaq notice immediately affect trading or operations of IRIDEX (IRIX)?
No. The company states the notice has no immediate impact on the listing and trading of its common stock, which will continue on the Nasdaq Capital Market during the Cure Period, and it does not affect ongoing business operations or SEC reporting requirements.
What actions is IRIDEX (IRIX) considering to address the Nasdaq bid price issue?
IRIDEX states it intends to actively monitor the closing bid price of its common stock and is considering all available options to regain compliance with the Minimum Bid Price Requirement, which could include a reverse stock split if necessary.
AI-generated analysis. How Rhea-AI works. Not financial advice.
